Results for this period
Interim period (second quarter)1 January 2026–30 June 2026Non-consolidated (standalone)Japanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ thousand).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
The regenerative medicine support business saw lower revenue and a larger loss due to sluggish overseas market sales amid prolonged political and geopolitical turmoil. The cell-sheet regenerative medicine business recorded higher revenue and a smaller loss. Overall, the operating loss narrowed as a result of ongoing cost reductions and other factors.
The filing includes disclosure regarding material events and conditions. Although the company believes that financing will ensure there are no immediate problems with cash management, the timing for obtaining approval and commercializing the first cell-sheet regenerative medicine product has not been determined, and conditions exist that raise significant doubt about the going-concern assumption. The notes to the financial statements contain no applicable going-concern matters.
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Non-consolidated (standalone) |
| Period Covered | 1 January 2026–30 June 2026 |
| Net Sales | ¥20 million (YoY -43.7%) |
| Operating profit | ¥-570 million |
| Ordinary income | ¥-576 million |
| Profit attributable to owners of the parent | ¥-610 million |
| Net income per share | -¥15.93 |
| Equity ratio | End of the current fiscal period 84.5 / End of previous period 76 |
| Total assets | ¥2,084 million |
| Net assets | ¥1,773 million |
| Cash flows from operating activities | ¥-566,236 thousand |
| Cash flows from investing activities | ¥-46,358 thousand |
| Cash flows from financing activities | ¥1,085,951 thousand |
| Cash and cash equivalents at end of period | ¥1,792,266 thousand |
| Full-year earnings forecast | Net Sales ¥71 million (YoY -14.9%) / Operating profit ¥-1,225 million / Ordinary income ¥-1,250 million / Net income ¥-1,320 million |
| Annual Dividend Forecast | ¥0 → ¥0（0.0%） |
| Segment revenue | Regenerative Medicine Support Business ¥16,342 thousand, Cell-sheet regenerative medicine business ¥4,477 thousand |
| Segment profit | Regenerative Medicine Support Business ¥-72,309 thousand, Cell-sheet regenerative medicine business ¥-364,306 thousand |
| Impairment loss | ¥33,515 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on reversal of subscription rights to shares ¥264 thousand / Extraordinary loss Impairment Losses ¥33,515 thousand |
| Disclosure regarding the going concern assumption | The filing includes disclosure regarding material events and conditions. Although the company believes that financing will ensure there are no immediate problems with cash management, the timing for obtaining approval and commercializing the first cell-sheet regenerative medicine product has not been determined, and conditions exist that raise significant doubt about the going-concern assumption. The notes to the financial statements contain no applicable going-concern matters. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Material subsequent events | From 1 July to 31 July 2026, 1,046 of the 25th Series Stock Acquisition Rights were exercised, and 104,600 shares were issued. Total exercise proceeds were ¥22,587 thousand, and the increase in stated capital was ¥11,314 thousand. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | No (a financial results briefing video is scheduled to be released) |
| Issued Shares at Period-End | 39,319,219 shares |
| Treasury Shares at Period-End | 156 shares |
| Factors Behind Changes in Business Performance | The regenerative medicine support business saw lower revenue and a larger loss due to sluggish overseas market sales amid prolonged political and geopolitical turmoil. The cell-sheet regenerative medicine business recorded higher revenue and a smaller loss. Overall, the operating loss narrowed as a result of ongoing cost reductions and other factors. |
Items this document does not state (8)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue in the regenerative medicine support business declined, mainly because sales in overseas markets remained sluggish amid prolonged political and geopolitical turmoil. Meanwhile, the operating loss narrowed as a result of ongoing cost reductions and higher revenue from the cell-sheet regenerative medicine business.